Over the past two decades nutritional support has rapidly become an integral part of the medical care of critically ill patients. As scientific evidence accumulates supporting the important role of underlying nutritional status in determining the eventual outcome of many illnesses, aggressive nutritional intervention has become commonplace in our medical and surgical ICUs. However, nutritional support, particularly parenteral alimentation, is expensive and associated with important morbidity and even mortality. Furthermore, definite evidence of its clinical efficacy under certain specific conditions is often lacking and in need of properly done prospective studies. This review summarizes the basic principles of nutrition as applied to the critically ill patient in the clinical setting. Special emphasis is on practical considerations regarding cost, efficacy (or lack thereof), and potential advantages, disadvantages, and risk of complications of each proposed approach.

Although thrombolytic agents have been available for over 10 years and have demonstrated safety and efficacy in an increasing number of clinical conditions involving thrombotic phenomena, their general acceptance as first-line therapeutic agents in medical management has been slow. Much of the reluctance to use these drugs is based on their associated incidence of hemorrhagic complications, which is several-fold greater than with use of conventional anticoagulants. With the introduction of second-generation thrombolytic agents, made possible through successes in recombinant DNA technology and chemical modifications of previously available compounds, increased fibrin specificity has been achieved and has been translated into increased clinical efficacy and safety. These results will likely improve as innovative regimens using dose modifications or multiple agents with combined synergy are developed. An appreciation of basic coagulation and the pharmacology of anticoagulants and thrombolytic agents is necessary to maximize the benefits of currently available medications, to develop new treatment strategies, and to minimize potential hemorrhagic complications.

Minimal resection with curative intent for bronchogenic carcinoma was performed at our institutions in 15 patients from 1977 to 1987. All patients were stage I (T1N0 or T2N0). The five-year actuarial survival was 77 percent. The median length of follow-up for patients remaining alive was 41 months. There was a 6 percent (n = 1) local recurrence rate and a 27 percent (n = 3) distant recurrence rate. Both survival and recurrence rates are similar for minimal resection and for that being reported for lobectomy and pneumonectomy for stage I bronchogenic carcinoma. In our series, both median length of operating time and median length of postoperative hospital stay was less for those patients undergoing minimal resection for stage I bronchogenic carcinoma than for those undergoing lobectomy or pneumonectomy. Minimal resection can be considered as an acceptable treatment for bronchogenic carcinoma when technically possible in selected patients.

Postinfluenza toxic shock syndrome is a recently described entity that results from a respiratory tract infection with toxin-producing Staphylococcus aureus following an episode of influenza or influenzalike illness. This report describes a 19-year-old man who developed an influenza B respiratory infection complicated by staphylococcal pneumonia and toxic shock syndrome. The patient improved rapidly with specific antibiotic therapy, emphasizing the importance of considering this otherwise highly lethal syndrome in any individual who becomes critically ill after an initial influenzalike illness.